Welcome to our dedicated page for Kazia Therapeuti SEC filings (Ticker: KZIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kazia Therapeutics Limited (NASDAQ: KZIA) files as a foreign private issuer with the U.S. Securities and Exchange Commission, primarily using Form 20-F for annual reporting and Form 6-K for current reports. This SEC filings page for KZIA brings together those regulatory documents and pairs them with AI-generated summaries to help readers interpret the company’s disclosures.
For a clinical-stage oncology company like Kazia, Form 6-K reports often incorporate press releases and transaction details by reference. Recent 6-K filings describe private placements of equity securities, the terms of pre-funded warrants and American Depositary Shares, at-the-market offering agreements, and collaboration and in-licensing arrangements such as the PD-L1 protein degrader program with QIMR Berghofer. Other 6-Ks discuss Nasdaq listing notices, the company’s responses, and subsequent steps taken to regain or demonstrate compliance with listing standards.
These filings also reference how capital raised is intended to support the continued clinical development of Kazia’s lead programs, including paxalisib, a brain-penetrant PI3K / Akt / mTOR pathway inhibitor, and EVT801, a VEGFR3 inhibitor, as well as the PD-L1 degrader program. Supplemental risk factor disclosures in certain filings provide additional detail on regulatory approval processes, combination therapy development, and ongoing regulatory obligations after any potential approvals.
On this page, AI-powered tools can help explain the structure and implications of Kazia’s 6-K filings, highlight key terms in financing agreements, and summarize how new collaborations or regulatory updates relate to the company’s oncology pipeline. Users can also review references to incorporated press releases, understand how offerings may affect capital structure, and see how Kazia describes its strategy for maintaining Nasdaq listing and advancing its investigational cancer therapies.
Kazia Therapeutics Limited is supplementing its prospectus to register 232,956 American Depositary Shares representing 116,478,000 Ordinary Shares. The supplement incorporates a Form 6-K disclosing the appointment of Dr. Sudha Rao as Chief Scientific Officer, effective April 13, 2026.
Dr. Rao will serve part-time (three days per week) with a base salary of AUD$325,000, a target annual bonus of 40%, and a proposed grant of 250,000 ADS options (one-third vest at commencement, remainder in two equal annual installments). The employment agreement permits concurrent work with QIMR Berghofer Medical Research Institute.
Kazia Therapeutics Limited files a prospectus supplement registering 95,110 American Depositary Shares (ADS) representing 47,555,000 Ordinary Shares. The supplement incorporates a Form 6-K reporting the appointment of Dr. Sudha Rao as Chief Scientific Officer, effective April 13, 2026, and summarizes her employment terms.
The Form 6-K discloses Dr. Rao’s part‑time (three days/week) role with an annual base salary of AUD$325,000, a target annual performance bonus of 40% of base salary, and a proposed grant of 250,000 ADS options (subject to Board approval) with staggered vesting. The ADSs trade on Nasdaq under the symbol KZIA (last reported sale price $9.46 per ADS as of April 14, 2026).
Kazia Therapeutics Limited files a prospectus supplement registering 10,700,211 American Depositary Shares (ADS), representing 5,350,105,500 ordinary shares, and incorporates a Form 6-K dated April 15, 2026 into that prospectus supplement. The supplement updates the Prospectus dated December 23, 2025 and includes a Form 6-K disclosing the appointment of Dr. Sudha Rao as Chief Scientific Officer, effective April 13, 2026.
Under an employment agreement, Dr. Rao will work part-time (three days per week) with an annual base salary of AUD$325,000, a target annual performance bonus of 40% of base salary, and a proposed grant of 250,000 ADS options subject to approval by the Company’s Board of Directors, with one-third vesting at commencement and the remainder vesting in two equal annual installments.
Kazia Therapeutics filed a prospectus supplement and Form 6-K updating its Registration Statement and furnishing a press release announcing the appointment of Dr. Sudha Rao as Chief Scientific Officer, effective April 13, 2026. The supplement states 266,666 American Depositary Shares representing 133,333,000 Ordinary Shares. The Form 6-K describes Dr. Rao’s part-time employment (three days per week), an annual base salary of AUD$325,000, a target annual performance bonus of 40% of base salary, and a proposed grant of 250,000 ADS options (subject to Board approval) with one-third vesting on commencement and the remainder vesting in two equal annual installments.
Kazia Therapeutics Limited has appointed Dr. Sudha Rao as Chief Scientific Officer under a new employment agreement. Effective April 13, 2026, she will serve part-time, three days per week, with an annual base salary of AUD$325,000 and a target annual bonus equal to 40% of base salary.
The agreement includes options to acquire 250,000 American Depositary Shares, with one-third vesting at commencement and the remainder vesting in equal tranches on the first and second anniversaries, subject to board approval. Dr. Rao will continue her role at QIMR Berghofer Medical Research Institute while leading Kazia’s scientific and R&D strategy.
Kazia Therapeutics Limited is registering 232,956 American Depositary Shares (ADSs) representing 116,478,000 Ordinary Shares under a prospectus supplement dated April 13, 2026. The company disclosed it entered a license and commercialisation agreement with QIMR Berghofer on April 10, 2026, under which Kazia obtained an exclusive worldwide license to a SETDB1-targeted epigenetic platform.
The agreement requires an upfront license payment of $1,390,000 payable within 15 business days of execution and a tiered revenue-sharing arrangement on commercialization revenue. The licensed program is in preclinical development; Kazia estimates combined costs of about $6 million over 18 months to advance the SETDB1 and PD-L1 degrader programs to IND readiness.
Kazia Therapeutics Limited files a prospectus supplement registering 266,666 American Depositary Shares representing 133,333,000 Ordinary Shares. The supplement incorporates a Form 6-K disclosing an exclusive, worldwide License and Commercialisation Agreement with QIMR Berghofer for a SETDB1-targeted epigenetic platform.
Under the agreement Kazia will pay an upfront license fee of $1,390,000 and a tiered revenue-sharing percentage on commercialization receipts; Kazia intends to advance the SETDB1 program in preclinical work toward IND-enabling studies in parallel with its PD-L1 degrader program.
Kazia Therapeutics Limited files a prospectus supplement registering 95,110 American Depositary Shares representing 47,555,000 Ordinary Shares pursuant to the Registration Statement on Form F-1, as supplemented by a Form 6-K furnished April 13, 2026.
The April 10, 2026 Form 6-K discloses Kazia's entry into an exclusive, worldwide license with QIMR Berghofer for a SETDB1-targeted epigenetic platform. Under the Agreement Kazia will pay an upfront license fee of $1,390,000 and agreed revenue-sharing percentages on commercialization revenue; Kazia plans IND-enabling work and to use commercially reasonable efforts to develop at least one product under the license.
Kazia Therapeutics Limited files a prospectus supplement registering 10,700,211 American Depositary Shares representing 5,350,105,500 ordinary shares in connection with its Form F-1 registration.
The supplement attaches a Form 6-K describing Kazia's April 10, 2026 license and commercialisation agreement with QIMR Berghofer, under which Kazia licensed a SETDB1-targeted epigenetic platform and agreed to pay an upfront license fee of $1,390,000. The Form 6-K and attached press release describe the licensed lead candidate MSETC, preclinical status, a projected $6 million combined cost to advance two preclinical programs to IND readiness over 18 months, and a tiered revenue-sharing structure with no clinical or regulatory milestone obligations.
Kazia Therapeutics Limited has entered a License and Commercialisation Agreement with QIMR Berghofer, gaining an exclusive worldwide license to develop and commercialize cancer therapies based on a proprietary SETDB1-targeted epigenetic platform.
Kazia will pay an upfront license fee of $1,390,000 and share a percentage of future commercialization revenue, with rates linked to the development stage at which any product is out-licensed. The lead candidate, MSETC, is a highly selective bicyclic peptide discovered using an AI-integrated epigenetic drug discovery engine and is designed to restore immune signaling in tumors resistant to immunotherapy.
The company plans to advance the SETDB1 and PD-L1 degrader programs through IND-enabling studies over about 18 months at a combined expected cost of approximately $6 million, leveraging shared CRO resources and Australian R&D tax incentives. Kazia views the SETDB1 platform as complementary to its existing oncology pipeline, which includes paxalisib and EVT801.